UBS Initiates Coverage On Iovance Biotherapeutics with Buy Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
UBS has initiated coverage on Iovance Biotherapeutics with a Buy rating and set a price target of $17.
October 24, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on Iovance Biotherapeutics with a Buy rating and a price target of $17, indicating a positive outlook for the stock.
The initiation of coverage by UBS with a Buy rating and a price target of $17 suggests a positive sentiment from a reputable financial institution. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100